title: [Carboplatin and cyclophosphamide in stage Ic-IV ovarian carcinoma: retrospective study of 101 cases].
abstract: We report our experience of CBDCA-CPM combination chemotherapy as first line therapy in 101 ovarian cancers. The therapeutic scheme was: initial cytoreductive surgery followed by six chemotherapy cycles (CBDCA 400 mg/m2/d IV dl, CPM 600 mg/m2/d IV dl, dl = d21) and second-look laparotomy. The initial stages were four Ic, three IIa, four IIb, four IIc, 15 IIIa, 28 IIIb, 23 IIIc and 20 IV. After initial surgery, there were 39 macroscopic residual diseases superior to 2 cm, 26 macroscopic residual diseases inferior or equal to 2 cm, four microscopic diseases and no residual disease in 30 cases (unknown in two cases). The overall response rate to chemotherapy was 83% with 56% histologic complete response rate. The main toxicity was haematological with 60% of leucopenia grade III-IV, 52% of thrombopenia grade III-IV. Age at diagnosis, residual disease after first look surgery and length of CA 125 normalization were significant prognostic factors for survival in this series.
authors.affiliation: Département d'oncologie, hôpital de Hautepierre, hôpitaux universitaires de Strasbourg, France.
authors.forename: T
authors.initials: T
authors.lastname: Petit
authors.forename: P
authors.initials: P
authors.lastname: Dufour
authors.forename: J C
authors.initials: JC
authors.lastname: Barrats
authors.forename: F
authors.initials: F
authors.lastname: Maloisel
authors.forename: B
authors.initials: B
authors.lastname: Duclos
authors.forename: C
authors.initials: C
authors.lastname: Giron
authors.forename: B
authors.initials: B
authors.lastname: Lioure
authors.forename: P
authors.initials: P
authors.lastname: Dellenbach
authors.forename: R
authors.initials: R
authors.lastname: Renaud
authors.forename: J
authors.initials: J
authors.lastname: Ritter
authors.forename: B
authors.initials: B
authors.lastname: Audhuy
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
authors.forename: F
authors.initials: F
authors.lastname: Oberling
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D003520:Cyclophosphamide; D016190:Carboplatin